This post hoc analysis of SINUS-52 (NCT02898454) assessed disease characteristics and response to dupilumab treatment in male and female patients with severe chronic rhinosinusitis with nasal polyps. The analysis found female patients had greater asthma, non-steroidal anti-inflammatory drug-exacerbated respiratory disease and health-related quality-of-life burden at baseline than male patients. Dupilumab treatment significantly improved objective and subjective outcomes compared with placebo through 52 weeks, irrespective of gender.

In this study, we found that patients with higher Epstein–Barr virus (EBV) DNA showed longer progression-free survival in pulmonary lymphoepithelioma-like carcinoma patients treated with immune checkpoint blockade. Plasma EBV DNA could be a useful biomarker to monitor disease progression and predict the efficacy of immune checkpoint blockade.

This study highlights the heterogenity of tumor and tumor-associated immune cells present in the circulation of advanced stage lung cancer patients.

In the analyses reported herein, we use data from clinical studies of the coronavirus disease 2019 (COVID-19) monoclonal antibody (mAb) combination AZD7442 (tixagevimab–cilgavimab) to demonstrate the utility of pseudovirus neutralisation assay data in conjunction with mAb serum concentrations to predict neutralising antibody titres against emergent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. Our findings offer a strategy to streamline the clinical evaluation of mAbs targeting SARS-CoV-2 and have the potential to significantly decrease the time from discovery to clinical deployment of the next generation of COVID-19 mAbs.